GlaxoSmithKline Pharma declines on reporting 43% fall in Q1 net profit

Glaxosmithkline Pharmaceuticals is currently trading at Rs 2475.00, down by 33.10 points or 1.32% from its previous closing of Rs 2508.10 on the BSE. The scrip opened at Rs. 2510.00 and has touched a high and low of Rs 2547.00 and Rs 2455.25 respectively. So far 2521 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3054.40 on 03-Mar-2014 and a 52 week low of Rs. 2155.00 on 29-Apr-2013. Last one week high and low of the scrip stood at Rs. 2561.00 and Rs. 2485.00 respectively. The current market cap of the company is Rs. 21218.53 crore. The promoters holding in the company stood at 75.00 % while Institutions and Non-Institutions held 11.46 % and 13.54 % respectively. GlaxoSmithKline Pharmaceuticals has reported results for first quarter ended March 31, 2014 The company has posted 42.88% fall in net profit at Rs 96.54 crore for the quarter ended March 31, 2014 as compared to Rs 169.00 crore for the same quarter in the previous year. Total income of the company has decreased by 8.28% at Rs 654.73 crore for quarter under review as compared to Rs 713.84 crore for the quarter ended March 31, 2013. GlaxoSmithKline Pharmaceuticals is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.